Wird geladen...
P01.109 Tumor treating fields treatment for patients with newly diagnosed glioblastoma: a cost-effectiveness analysis for Sweden
BACKGROUND: Glioblastoma (GBM) is the most aggressive form of primary brain cancer in adults. The EF-14 Trial in GBM patients reported a 5-year survival rate of 13% for newly diagnosed GBM patients treated with TTFields and maintenance temozolomide (TMZ) chemotherapy. The cost-effectiveness of addin...
Gespeichert in:
| Veröffentlicht in: | Neuro Oncol |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Oxford University Press
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6144379/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.151 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|